PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Follitropin Beta→

Follitropin Beta PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
150490-85-0
Molecular formula
C538H834N148O164S13
Molecular weight
~30000 g/mol
Drug class
Recombinant human follicle-stimulating hormone (FSH) gonadotropin
Mechanism of action
Activates FSH receptors on ovarian granulosa cells to stimulate follicular growth and development. In male fertility regimens, FSH receptor activation on Sertoli cells supports spermatogenesis when used with human chorionic gonadotropin.
Indications / reported uses
  • Controlled ovarian stimulation to develop multiple follicles in women undergoing assisted reproductive technology
  • Induction of ovulation in selected women with anovulatory infertility
  • Stimulation of spermatogenesis in selected men with hypogonadotropic hypogonadism when used with hCG; product-specific criteria apply

Sources: EMA EPAR — Puregon (follitropin beta) · US DailyMed — Follitropin beta · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Follitropin Beta PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Follitropin Beta Permitted Daily Exposure (PDE) report (the Follitropin Beta PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Follitropin Beta Occupational Exposure Limit (OEL) report (the Follitropin Beta OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.